Alar Breaks Key Barriers in Ketamine Therapy with Positive Phase 1 Results for Long-Acting Injectable ALA-3000 for Treatment-Resistant Depression
By reducing dissociation and sedation risk, ALA-3000 may eliminate the ≥2-hour post-dose monitoring requirement, reducing clinic operating costs, improving patient throughput, and supporting a more cost-effective and reimbursement-aligned treatment model. TAICHUNG, April 6, 2026...
CP
cision pr newswire
via Pr Newswire - Corroborated by 1 others
Updated 1h ago
Source Verification
Corroboration Score: 2This story was independently reported by 2 sources. Click any source to read the original article.
Comments
0 commentsBe respectful and constructive.
Loading comments...
Previous
Scientists may finally detect hidden ripples in spacetime - ScienceDaily
Next
Savannah Guthrie back at 'Today' anchor desk for the first time since her mother's disappearance
Related Articles
HealthCovista Expands Michael Betz's Role to Chief Growth & Innovation Officer
Businesswire-13h ago-1 sources
HealthFrazier Life Sciences Appoints Christian Schade as Senior Advisor
Businesswire-13h ago-1 sources
HealthAvant Healthcare Professionals Expands the “Dream. Become. Inspire.” Nursing Scholarship Worldwide, Opening New Pathways for Future Nurses
Businesswire-13h ago-1 sources